ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, today announced that it will display the LifeVest® Wearable Defibrillator in Booth #209 at the American Association of Heart Failure Nurses (AAHFN) Annual Meeting being held from June 23-25 in Seattle.
Heart failure is estimated to afflict approximately 5 million Americans and this number is expected to double in the next five years. The risk of sudden cardiac death (SCA) following a myocardial infarction is the highest in the first 30 days, and patients with heart failure following myocardial infarction are at 4-6 times greater risk.
The LifeVest Wearable Defibrillator is worn by patients at risk for SCA, providing protection during their changing medical condition, and until their permanent risk of SCA is established. The LifeVest protects these patients during this time of highest risk while they are being optimized on medical therapy. A patient’s condition can improve from the benefits of medical therapy, including meaningful improvement to the amount of ejection fraction. However, medical therapy and stabilization can take up to three months or more, which is why wearing a LifeVest is so important.
“Nearly 550,000 new cases of heart failure are diagnosed every year in the United States. These patients experience sudden cardiac arrest at six to nine times the rate of the general population,” said Richard A. Packer, Chief Executive Officer of ZOLL. “The LifeVest is an important therapy in the continuum of care for patients with heart failure, allowing a physician to manage a patient’s changing condition while protecting him or her from sudden cardiac arrest.”
The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.
The LifeVest is used for a wide range of patient conditions or situations, including following a heart attack, before or after bypass surgery or stent placement, as well as for those with cardiomyopathy or congestive heart failure that places them at particular risk.
The LifeVest is covered by most health plans in the United States, including commercial, state, and federal plans. To date, the LifeVest has been prescribed to more than 40,000 patients.
About ZOLL Medical Corporation
ZOLL Medical Corporation (zoll.com) develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.
A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company in 2007, 2008, and 2009, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe.
Copyright © 2011 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. LifeVest and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. All product names are the property of their respective owners.